8TE Stock Overview
Engages in the retail and wholesale of products based on hemp containing cannabidiol (CBD) in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cannabis Poland S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.12 |
| 52 Week High | zł0.18 |
| 52 Week Low | zł0.03 |
| Beta | 0.78 |
| 1 Month Change | 0% |
| 3 Month Change | -1.74% |
| 1 Year Change | 314.67% |
| 3 Year Change | -76.17% |
| 5 Year Change | n/a |
| Change since IPO | 22.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8TE | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | 0.3% |
| 1Y | 314.7% | -16.3% | 6.9% |
Return vs Industry: 8TE exceeded the German Pharmaceuticals industry which returned -30.8% over the past year.
Return vs Market: 8TE exceeded the German Market which returned 0.9% over the past year.
Price Volatility
| 8TE volatility | |
|---|---|
| 8TE Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8TE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 8TE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 2 | Michal Szary | www.cp-sa.pl |
Cannabis Poland S.A. engages in the retail and wholesale of products based on hemp containing cannabidiol (CBD) in Poland. The company sells CBD oils and herbs, inhalers, and vaporizers, as well as cosmetics. It sells its products through HempWish.pl and Vapem.eu online stores.
Cannabis Poland S.A. Fundamentals Summary
| 8TE fundamental statistics | |
|---|---|
| Market cap | €6.54m |
| Earnings (TTM) | -€284.26k |
| Revenue (TTM) | €15.21k |
430.1x
P/S Ratio-23.0x
P/E RatioIs 8TE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8TE income statement (TTM) | |
|---|---|
| Revenue | zł65.55k |
| Cost of Revenue | zł95.35k |
| Gross Profit | -zł29.80k |
| Other Expenses | zł1.20m |
| Earnings | -zł1.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -0.025 |
| Gross Margin | -45.46% |
| Net Profit Margin | -1,869.25% |
| Debt/Equity Ratio | 8.1% |
How did 8TE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/20 05:00 |
| End of Day Share Price | 2024/01/22 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cannabis Poland S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|